CD47 and neoplasm: Since RTX-IgG2 was capable of altering and reducing the expression of CD47 on the target Granta-519 cells (Figure 4), we hypothesized that a pre-treatment of Granta-519 cells with RTX-IgG2 would enhance the efficacy of other tumor-targeting mAbs to induce ADCP.